Nuvo Research® and NovaMedica sign agreement to market Pennsaid® in Russia

  Nuvo Research® and NovaMedica sign agreement to market Pennsaid® in Russia

PR Newswire

MISSISSAUGA, ON and MOSCOW, Dec. 19, 2013

MISSISSAUGA, ON and MOSCOW, Dec. 19, 2013 /PRNewswire/ - Nuvo Research Inc.
(TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of
products in the areas of topical pain and immunology, and NovaMedica LLC
(NovaMedica), a Russian pharmaceutical company, today announced that they have
signed a supply and distribution agreement providing NovaMedica the exclusive
rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in
Russia and some of the Community of Independent States (CIS).

Pennsaid 1.5% and  Pennsaid 2%  are used  to treat  the symptoms  and pain  of 
osteoarthritis of the  knee. Pennsaid 1.5%  is approved by  the U.S. Food  and 
Drug Administration (FDA) and is currently being marketed in the U.S.,  Canada 
and certain European countries. A new  drug application (NDA) for Pennsaid  2% 
is currently under review by  the FDA which has  indicated that it expects  to 
respond to the NDA by February 7, 2014.

Under the terms  of the  agreement, NovaMedica is  responsible for  conducting 
required clinical studies and obtaining  regulatory approval for the  products 
in the licensed territories. Sales of Pennsaid 1.5% in Russia are projected to
begin in 2015.

"With an  established  sales force  and  excellent knowledge  of  the  Russian 
pharmaceutical market, NovaMedica  is the ideal  commercial partner to  obtain 
approval for and  market Pennsaid 1.5%  and Pennsaid 2%  in Russia," said  Dan 
Chicoine, Chairman and Co-CEO of  Nuvo. "Pennsaid 1.5% is currently  marketed 
in five countries,  and we  will continue to  expand its  market potential  by 
seeking marketing partners throughout the world."

"This  agreement  brings  together  the  advanced  expertise  and   innovative 
scientific potential  of  Nuvo  Research  and  our  clinical,  regulatory  and 
commercial  capabilities  in  Russia,  an  ideal  combination  to  bring  this 
innovative drug to Russian and CIS  patients. We expect these products have  a 
big potential to become an effective and safe solution for unmet needs in  our 
markets," said Fabrice Egros, COO of NovaMedica. "Our company is committed to
contribute to the  improvement of  Russian health  care and  will continue  to 
address the Russian market with innovative medicines."

About Pennsaid 1.5%
Pennsaid is  used  to  treat  the signs  and  symptoms  associated  with  knee 
osteoarthritis (OA). The  drug combines the  transdermal carrier  (containing 
dimethyl sulfoxide, popularly known  as DMSO) with  1.5% diclofenac sodium,  a 
non-steroidal anti-inflammatory  drug (NSAID)  and  delivers the  active  drug 
through the skin directly to the  site of inflammation and pain. Pennsaid  is 
currently marketed in  the United States  by Mallinckrodt Inc.,  in Canada  by 
Paladin Labs Inc. and marketed under license and/or distribution agreements in
Greece, Italy and the United Kingdom.

About Pennsaid 2%
Pennsaid 2% is a follow-on product to original Pennsaid. Pennsaid 2% contains
2% diclofenac  sodium compared  to 1.5%  for original  Pennsaid. It  is  more 
viscous than original Pennsaid, is supplied in a metered dose pump bottle  and 
was studied in clinical trials using twice daily dosing compared to four times
a day for original Pennsaid. In  August 2013, Mallinckrodt advised Nuvo  that 
the FDA accepted a resubmission of  a New Drug Application (NDA) for  Pennsaid 
2% for  review and  set  a Prescription  Drug User  Fee  Act (PDUFA)  date  of 
February 7, 2014 for action on the submission.

About Nuvo Research Inc.
Nuvo (TSX:NRI)  is a  specialty pharmaceutical  company focused  on  improving 
patient's lives  by developing  and commercializing  innovative products  that 
address unmet medical needs. Nuvo has  a diverse portfolio of products in  the 
areas of topical pain and immunology.

Nuvo's marketed products include Pennsaid^® (a topical treatment for the signs
and symptoms  of  osteoarthritis  of  the knee),  Pliaglis  (a  topical  local 
anesthetic) and  the  heated  lidocaine/tetracaine  patch  (HLT  Patch).  For 
additional Company information visit www.nuvoresearch.com.

About NovaMedica
NovaMedica is  a Russian  pharmaceutical company  established in  2012 by  DRI 
Holdings Limited, a portfolio  company of Domain  Associates LLC, and  Russian 
investment corporation  RUSNANO, which  implements  government policy  on  the 
development  of  hi-tech  industries.   NovaMedica's  strategy  is  aimed   at 
localizing production of a wide range of new medicines and technologies in the
Russian market,  including screening  and registration,  and the  creation  of 
innovative GMP-standard manufacturing facilities. www.novamedica.com.

Forward-Looking Statements

Certain statements in this news release constitute forward-looking  statements 
within the meaning of applicable securities laws. Forward-looking  statements 
include,  but  are  not  limited  to,  statements  concerning  Nuvo's   future 
objectives, strategies to achieve those objectives, as well as statements with
respect to management's beliefs, plans, estimates, and intentions, and similar
statements  concerning  anticipated  future  events,  results,  circumstances, 
performance or expectations  that are not  historical facts.  Forward-looking 
statements  generally  can  be  identified  by  the  use  of   forward-looking 
terminology such as "outlook", "objective", "may", "will", "expect", "intend",
"estimate", "anticipate",  "believe",  "should",  "plans"  or  "continue",  or 
similar   expressions   suggesting   future   outcomes   or   events.    Such 
forward-looking statements reflect management's current beliefs and are  based 
on information currently available to management. Forward-looking  statements 
involve risks  and uncertainties  that could  cause actual  results to  differ 
materially from those  contemplated by  such statements.  Factors that  could 
cause such differences include the need for additional financing, the  current 
economic  environment,  dependence  on   sales  and  marketing   partnerships, 
competitive developments, as  well as  other risk factors  included in  Nuvo's 
annual information form dated March 27, 2013 under the heading "Risks Factors"
and as described  from time to  time in the  reports and disclosure  documents 
filed by Nuvo with Canadian  securities regulatory agencies and  commissions. 
This  list  is  not  exhaustive  of   the  factors  that  may  impact   Nuvo's 
forward-looking statements.  These and  other  factors should  be  considered 
carefully  and   readers   should  not   place   undue  reliance   on   Nuvo's 
forward-looking statements. As a result  of the foregoing and other  factors, 
no assurance can be given as to any such future results, levels of activity or
achievements and neither Nuvo nor any other person assumes responsibility  for 
the accuracy  and  completeness  of  these  forward-looking  statements.  The 
factors underlying current  expectations are dynamic  and subject to  change. 
Although the forward-looking  information contained  in this  news release  is 
based upon what management believes  are reasonable assumptions, there can  be 
no assurance that actual results will be consistent with these forward-looking
statements.  Certain  statements  included  in  this  news  release  may   be 
considered "financial outlook" for purposes of applicable securities laws, and
such financial outlook  may not be  appropriate for purposes  other than  this 
news release.  All  forward-looking  statements  in  this  news  release  are 
qualified by  these  cautionary statements.  The  forward-looking  statements 
contained herein are made as  of the date of this  news release and except  as 
required by applicable law, Nuvo  undertakes no obligation to publicly  update 
or  revise  any  forward-looking  statement,  whether  as  a  result  of   new 
information, future events or otherwise.



SOURCE Nuvo Research Inc.

Contact:

NovaMedica LLC
Elena Pochesneva
Director of Public Relations
Email:pochesneva@team-drive.ru
Tel: +7 916025 9610

Nuvo Research Inc.
Christina Cameron
Director, Investor Relations & Corporate Communications
Email:ccameron@nuvoresearch.com
Tel: +1 (905) 673-3617